The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes

Area of Science:

• Neuroscience
• Endocrinology
• Pharmacology

Background:

• Interleukin-6 (IL-6) is a cytokine with roles in immune response, hematopoiesis, and neural development.
• Diabetic neuropathy is a common complication characterized by nerve dysfunction and impaired neurovascular function.

Purpose of the Study:

• To investigate the potential of IL-6 treatment to reverse early neurovascular and functional deficits in experimental diabetes.
• To assess the dose-dependent effects of IL-6 on nerve conduction, pain sensitivity, and nerve blood flow in diabetic rats.

Main Methods:

• Streptozotocin-induced diabetic rats were treated with varying doses of IL-6 for four weeks.
• Nerve conduction velocity (motor and sensory), thermal hyperalgesia, tactile allodynia, and sciatic nerve endoneurial blood flow were measured.

Main Results:

• IL-6 treatment dose-dependently corrected reductions in motor and sensory nerve conduction velocity.
• Complete correction of thermal hyperalgesia and tactile allodynia was observed, while mechanical hyperalgesia remained unaffected.
• Diabetes-induced reduction in sciatic nerve blood flow was restored to normal levels by IL-6 treatment.

Conclusions:

• IL-6 treatment ameliorates several key measures of nerve dysfunction in experimental diabetes.
• The beneficial effects of IL-6 are associated with improved nerve blood flow, suggesting a dual neurotrophic and vascular action.
• IL-6 shows promise as a potential therapeutic agent for clinical trials in diabetic neuropathy.